2011 seminar schedule

50th Anniversary events

Biodosimetry: Tools

Emergency Response Resources
Advisory team
Other resources

Managing Radiation Casualties
POLICIES
Depleted uranium (PDF)
Potassium iodide (PDF)
Prussian blue (PDF)
PUBLICATIONS
Emergency radiation
  medicine response (PDF)
Management of
  radiological casualties (PDF)
Planning guidance: Response
  to a nuclear detonation (PDFs)
  • 1st Edition (Jun 2009)
  • 2nd Edition (Jun 2010)
NCRP recommendations (PDF)
Textbook: Consequences
  of nuclear warfare

Medical Effects of Ionizing Radiation
Course description
Schedule, fees, registration
Course resources

Products: Quick List
Exposure assessment tools
Forms
Guidance

Publications
Books/book chapters
Contract reports/films
Journal articles/supplements
Reports/report chapters
Scientific reports
Special publications
Technical reports

Register AFRRI Products

Research: Programs
• Biological dosimetry
• Radiation injury combined
   with other trauma
• Internal contamination
   and metal toxicity
• Radiation countermeasures

Seminars: Schedule

USU Graduate
Education: Radiation Biology

You are here: HOME > Seminars > 2011 seminar schedule
Seminars
Jump to: 2012 \| 2011 \| 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2003
Venue
Time: 10:30 to 11:30 a.m. (unless otherwise noted) each Friday Place: AFRRI Conference Room, unless otherwise indicated.
Directions to AFRRI \| Base map \| Security, base access, parking
Seminars are presented by AFRRI researchers and other members of the scientific community. While some seminars are open to the public, others are limited to specific audiences. Any exceptions to time, place, and admittance are noted with each item. We do not record or distribute information presented in our Seminar Program. However, where available, references to related information are provided with the seminar title.
2011 seminar schedule
Friday, December 9: Sanchita P. Ghosh, PhD, Research Biologist, Radiation Countermeasures Program, AFRRI: Toxicity, survival and DRF—A comparative study of tocols. Related information: Hematological targets of radiation damage. Curr Drug Targets 11:1375–1385, 2010. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiat Res. 173:738–747, 2010. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol. 85:598–606, 2009. Friday, December 2: Olcay Y. Jones, MD, PhD, Chief, Division of Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD: Mesenchymal stem cell transplant of BXSB lupus mice: A model for studying regeneration of vascular endothelial cells and hepatocytes. Related information: Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice. Lupus. 18:813–821, 2009. Comparison of treatment-response criteria for juvenile idiopathic arthritis. Nat Clin Pract Rheumatol. 2:466–467, 2006. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. J Clinical Rheumatol. 12:83–86, 2006. Friday, November 4: Mang Xiao, MD, Research Biologist, Radiation Countermeasures Program, AFRRI: Micro-RNA 30 regulates survival protein-REDD1 expression in human hematopoietic CD34+ cells and osteoblast cells after gamma-irradiation. Related information: Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma-irradiation through Erk/mTOR signaling. Haematologica 95:1996–2004, 2010 Pharmacological countermeasures for the acute radiation syndrome. Curr Mol Pharmacol. 2 :122–133, 2009. Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury. Exp Hematol. 37:52–64, 2009. Friday, October 28 (10:00 a.m.): Alexandra C. Miller, PhD, Senior Research Scientist, Radiation Countermeasures Program, AFRRI: Radiation leukemia: Models and mechanisms. Related information: Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys. 2011 Sep 3. [Epub ahead of print] Preconceptional paternal exposure to depleted uranium: Transmission of genetic damage to offspring. Health Phys. 99:371–379, 2010 A review of depleted uranium biological effects: In vitro and in vivo studies. Rev Environ Health, 22:75–89, 2007. Friday, September 23: David D. Roberts, PhD, Chief, Biochemical Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD: Therapeutic opportunities for targeting thrombospondin-1 and its receptor CD47 to control radiation and ischemic stress injuries. Related information: sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration. Arch Biochem Biophys. 509:147–156, 2011. ATP binding to hemoglobin response gene-1 protein is necessary for regulation of the mating type locus in Candida albicans. J Biol Chem. 286:13914–13924, 2011. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem. 286: 14991–15002, 2011. Friday, September 16: Vijay K. Singh, PhD, Radiation Countermeasure Program, AFRRI, Department of Radiation Biology, F. Edward Hébert School of Medicine, USUHS: CBLB613: A TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Related information: Tocopherol succinate: Modulation of antioxidant enzymes and oncogene expression, and hematopoietic recovery. Intl J Radiat Oncol Biol Phys. 79:571–578, 2011. Preclinical development of a bridging therapy for radiation casualities. Expt Hematol. 38:61–70, 2010. Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor. Int J Rad Biol. 86:12–21, 2010. Friday, September 9: David L. Bolduc, PhD, Research Microbiologist, Combined Injury group, AFRRI: Development of an algorithm for predicting "relative risk" of terrorist-CBRN and its potential applications in radiation biology. Friday, July 8: Shilpa S. Kulkarni, PhD, Staff Investigator, Henry M. Jackson Foundation (Radiation Countermeasures Program, AFRRI), Bethesda, MD: Development of gamma tocotrienol as a radiation countermeasure: Efficacy and mechanisms. Related information: Pentoxifylline enhances the radioprotective properties of gamma-tocotrienol: Differential effects on hematopoietic, gastrointestinal and vascular systems. Radiat Res. 175:297–306, 2011. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total body irradiation. Radiat Res. 173:738–747, 2010. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Intl J Rad Biol. 85: 598–606, 2009. Friday, July 1: Venkataraman Srinivasan, PhD, Research Biologist, Radiation Countermeasures Program, AFRRI: Toxicity studies of Alxn4100TPO, a thrombopoietic mimetic in mice. Related information: Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic, as a radiation countermeasure. Immunopharmacol Immunotoxicol. 30:271–290, 2008. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxident gamma-tocotrienol. Life Sciences 78:2099–2104, 2006. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol. 23:379–385, 2003. Friday, June 24: John F. Kalinich, PhD, Program Advisor, Internal Contamination and Metal Toxicity Program, AFRRI: Internal Contamination and Metal Toxicity Program at AFRRI. Related information: The use of established skeletal muscle cell lines to assess potential toxicity from embedded metal fragments. Toxicology In Vitro 23:356–359, 2009. Protocol for the assessment of potential health effects from embedded metal fragments. Mil Med. 174:265–269, 2009. Embedded weapons-grade tungsten alloy shrapnel rapidly induces metastatic high-grade rhabdomyosarcoma in F344 rats. Environmental Health Perspectives 113:729–734, 2005. Friday, June 17: Andrew D. Cardon, MS, Director of State and Legal Affairs, and Matthew R. Bailey, BA, National Association for Biomedical Research, Washington, DC: Legal and political aspects of the animal-rights movement. Friday, May 27: Nagesh Bhatt, PhD, Post-doctoral fellow (Henry M. Jackson Foundation), Radiation Biodosimetry Program, AFRRI: Biodosimetry for triage management: Lessons from past incidents. Related information: Dose rate effect of pulsed electron beam on micronucleus frequency in human peripheral blood lymphocytes. Arh Hig Rada Toksikol. 61:77–83. Differential activation of mitogen-activated protein kinases following high and low LET radiation in murine macrophage cell line. Mol Cell Biochem. 324:85–91. The effect of electron and gamma irradiation on the induction of micronuclei in cytokinesis-blocked human blood lymphocytes. Radiat Environ Biophys. 48(2):197–203. Friday, May 20: Carolyn J. Fisher, PhD, Post-doctoral Associate (Corbin), Radiation Biodosimetry Program, AFRRI: Regulation of cancer cell radiosensitivity. Related information: Efficacy of sunitinib and radiotherapy in a genetically engineered mouse model of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 74:1207–1216, 2009. Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells. Cancer Biology & Therapy, 7:1271–1279, 2008. Friday, April 29: LT Joshua M. Swift, PhD, Combined Injury Program, AFRRI: Bone biology and the impact of low-dose radiation. Related information: Increased training loads do not magnify cancellous bone gains with rodent jump resistance exercise. J Appl Physiol. 109:1600–1607, 2010. Simulated resistance training during hindlimb unloading abolishes disuse bone loss and maintains muscle strength. J Bone Miner Res. 25:564–574, 2010. Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat. J Endocrinol. 199:379–388, 2008. Friday, April 22: CPT Ian C. Dews, PhD, Combined Injury Program, AFRRI: The four syndecas: A fugue in GxxxG minor. Related information: Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/G-protein fusion protein. J Pept Res. 60:336–347, 2002 Friday, April 15: Akhilesh Nagaich, PhD, Principal Investigator, Division of Therapeutic Proteins, CDER, Food and Drug Administration, Bethesda, MD: Steroid receptor dynamics and chromatin remodeling. Related information: p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. J Biol Chem. 285:1321–132, 2010. Chromatin dynamics and the evolution of alternate promoter states. Chromosome Res. 14:107–116, 2006. E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation. Cancer Res. 65:4067–4077, 2005. Friday, April 8: Sugata Ray, PhD, Staff Investigator (Henry M. Jackson Foundation), Radiation Countermeasures Program, AFRRI: Platelet-derived growth Factor D and its key role in lens cell proliferation. Related information: A role for lengsin, a recruited enzyme, in terminal differentiation in the vertebrate lens. J Biol Chem. 283: 6607–6615, 2008. Endogenous retroviral insertion in Cryge in the mouse No3 cataract mutant. Genomics 89:512–520, 2007. Platelet-derived growth factor D, tissue-specific expression in the eye, and a key role in control of lens epithelial cell proliferation. J Biol Chem. 280:8494–8502, 2005. Friday April 1: Pankaj K. Singh, PhD, National Research Council—Research Associate, Radiation Countermeasures Program, AFRRI: Tocopherol succinate ameliorates radiation-induced GI syndrome: Mechanistic approach. Related information: Podophyllum hexandrum fraction (REC-2006) shows higher radioprotective efficacy in the p53-carrying hepatoma cell line: A role of cell cycle regulatory proteins. Integr Cancer Ther. 8:261–272, 2009 Pifithrin-alpha decreases the radioprotective efficacy of a Podophyllum hexandrum Himalayan mayapple fraction REC-2006 in HepG2 cells. Biotechnol Appl Biochem. 54:53–64, 2009. Podophyllum hexandrum (Himalayan mayapple) extract provides radioprotection by modulating the expression of proteins associated with apoptosis. Biotechnol Appl Biochem. 42:81–92, 2005. Friday, March 25: William F. Blakely, PhD, Program Advisor, Biological Dosimetry, AFRRI: Partial-body biodosimetry: Preliminary results using a mouse radiation exposure model. Related information: Biodosimetry assessment tool (BAT) software-dose prediction algorithms. Health Phys. 99:S171–183, 2010 Biodosimetry medical recording—Use of the Biodosimetry Assessment Tool. Health Phys. 99:S184–191, 2010 Multiple parameter radiation injury assessment using a nonhuman primate radiation model—Biodosimetry applications. Health Phys. 98:153–159, 2010 Friday, March 18: G. David Ledney, PhD, Research Biologist, Combined Injury Program, AFRRI: Title to be announced. Related information: Combined injury: Factors with potential to impact radiation dose assessments. Health Physics 98: 145–152, 2010. Resident bacteria in a mixed population of rhesus macaque (Macaca mulatta) monkeys: A prevalence study. J Med. Primatology 38:397–403, 2009. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res. 172:686–697, 2009. Friday, March 11: Gregory L. King, PhD, Research Physiologist, Biodosimetry Program, AFRRI: Title to be announced. Related information: 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. Aviat Space Environ Med. 70:485–492, 1999. Plasticity of the emetic response after irradiation in the conscious ferret. Am J Physiol. 265: R1092–R1099, 1993. Characterization of radiation-induced emesis in the ferret. Radiat Res. 114:599–612, 1988. Friday, March 4: Michael R. Landauer, PhD, Research Toxicologist, AFRRI: Discovery and development of genistein as a radiation countermeasure agent. Related information: Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol. 38: 270–281, 2010. Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice. Int Immunopharmacol. 9:1401–1410, 2009. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol. 84:713–726, 2008. Friday February 25: Kushal Chakraborty, PhD, Staff Investigator (Henry M. Jackson Foundation), Radiation Countermeasures Program, AFRRI: Detoxification by UDP-glucuronosyltransferases and role of PKC. Related information: The major chemical-detoxifying system of UDP-glucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J Biol Chem. 283:23048–23061, 2008. The role of nitric oxide in aspirin-induced thrombolysis in vitro and the purification of aspirin-activated nitric oxide synthase from human blood platelets. Am J Hematol. 82: 986–995, 2007. Restoration by aspirin of impaired plasma maspin level in human breast cancer. Acta Oncologica 45:184–187, 2006. Friday, February 18: K.S. Kumar, PhD, Research Chemist, Radiation Countermeasures Program, AFRRI: Tocols—naturally occurring small molecules with pharmacological significance. Related information: Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiat Res. 173:738–747, 210. Gamma-tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiat Res. 171:596–605, 2009. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol. 85:598–606, 2009. Friday, February 11: Ji Ming Wang, MD, PhD, Senior Principal Investigator, Tenured, Laboratory of Molecular Immunoregulation, Center for Cancer Research, NCI-Frederick, MD: The role of the G-protein couple formylpeptide receptors in cancer and inflammation. Related information: A critical role for the G-protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol. 184: 3331–3315, 2010. The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells. Br J Cancer 102:1052–1060, 2010. Synergy of TRIF-dependent TLR3 and MyD88-dependent TLR7 in up-regulating expression of mouse FPR2, a promiscuous G-protein-coupled receptor, in microglial cells. J NeuroImmunol 213:69–77, 2009. Friday, February 4: Natalia I. Ossetrova, PhD, Research Biologist, Biological Dosimetry Program, AFRRI: Protein biomarkers as a complementary approach to conventional biodosimetry for radiation injury and exposure dose assessment. Related information: Multiple parameter radiation injury assessment using a nonhuman primate radiation model—Biodosimetry applications. Health Phys. 98:153–159, 2010. Combined approach of hematological biomarkers and plasma protein SAA for improvement of radiation dose assessment in triage biodosimetry applications. 2010. Health Phys. 98: 204–208, 2010. Multiple blood-proteins approach for early-response exposure assessment using an in vivo murine radiation model. Intl J Rad Biol. 85:837–850, 2009. Friday, January 28: Alina V. Brenner, MD, PhD, MPH, Staff scientist, Radiation Epidemiology Branch, Division of Cancer Epidemiology and genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD: Thyroid cancer and other thyroid diseases among individuals exposed to iodine 131 from the Chornobyl accident in childhood or adolescence. Related information: Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident. Br J Cancer 2010 [Epub ahead of print]. Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer. 2010 [Epub ahead of print]. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev. 18:1651–1658, 2009. Friday, January 21: Lynnette Cary, PhD, Research Assistant Professor (Henry M. Jackson Foundation), Radiation Countermeasures Program, AFRRI: Endothelial cell regulation of hematopoietic cells after radiation injury. Related information: Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. Radiat Res. 173:319–332, 2010. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res. 172:686–697, 2009. Epidermal growth factor receptor pathway substrate 8 is over expressed in human pituitary tumors: Role in proliferation and survival. Endocrinology 150:2064–2071, 2009. Friday, January 14: Maria Moroni, PhD, Research Associate (Henry M. Jackson Foundation), Radiation Countermeasures Program, AFRRI: Development of Gottingen minipig as radiation injury model. Related information: Triage dose assessment for partial-body exposure: Dicentric analysis. Health Physics 98:244–251, 2010. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients. Cancer Immunol Immunother. 56:1711–1721, 2007. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 64:7346–354, 2004. Friday, January 7: Wan Jiao, MD, PhD, Scientist (Henry M. Jackson Foundation), Combined Injury Program, AFRRI: Selective cyclooxygenase-2 (COX-2) inhibitors lack immunomodulatory effects on radiation combined injury. Related information: Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. Radiat Res. 173:319–332, 2010. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res. 172:686–697, 2009. Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 27:3156–3164, 2008.
TOP OF PAGE


USU site index \| USU home			AFRRI home \| Text version \| A–Z Index \| Site map
No Fear Act \| Privacy/Security notice			RSS feeds \| Disclaimer \| Copyright